Fundraising FoxHelixbind
Marlborough, US · Founded 2012 · Delaware corporation · 1 known investors
Find your way into Helixbind
Sign up to see every warm intro you have to Helixbind
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Helixbind team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
HelixBind develops a diagnostic platform for bloodstream infections that delivers microbiology results in about 4 hours to help clinicians identify invasive infections and choose antimicrobial treatments. Its technology targets sepsis diagnosis and aims to support faster, more accurate pathogen identification for hospitals and physicians.
Founders & leadership
Helixbind was founded in 2012 by Alon Singer.
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.5M disclosed across 2 rounds · 2014–2017
▶$2.9MraisedOct 2017 · 29 investors · BiotechnologyRule 506(b)
- Alon SingerExecutive Officer, Director, Promoter
- Larry PearsonDirector
- Sheppard MollickDirector
- Offering amount
- $2.9M
- Amount sold
- $2.9M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$1.6MraisedFeb 2014 · 14 investors · BiotechnologyRule 506(b)
- Larry PearsonDirector
- Alon SingerExecutive Officer, Director, Promoter
- Sheppard MollickDirector
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 18 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $2.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $299.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $177.6K |
| National Science Foundation | Phase I | 2013 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Helixbind do?
- HelixBind develops a diagnostic platform for bloodstream infections that delivers microbiology results in about 4 hours to help clinicians identify invasive infections and choose antimicrobial treatments. Its technology targets sepsis diagnosis and aims to support faster, more accurate pathogen identification for hospitals and physicians.
- Who founded Helixbind?
- Helixbind was founded by Alon Singer in 2012.
- Who are Helixbind's investors?
- Helixbind's investors include Arieal Southeast Angel Partners.
- How much funding has Helixbind raised?
- Helixbind has disclosed $4.5M raised across 2 rounds.
- Where is Helixbind headquartered?
- Helixbind is headquartered in Marlborough, US.